Case Report Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Signiﬁcantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver 1,2 2 3 2 Junichi Okada, Shunichi Matsumoto, Kyoichi Kaira, Tsugumichi Saito, 2 4 5 6 Eijiro Yamada, Hideaki Yokoo, Ryuji Katoh, Motoyasu Kusano, 2 2 Shuichi Okada, Masanobu Yamada Clinical Clinical Practice Practice Points Points A 69-year-old male patient had been regularly visiting His cancer cells had become resistant to 2 combina- our hospital to manage his sigmoid colon cancer with tion chemotherapy regimens; thus, monotherapy with multiple liver metastases since he had undergone cetuximab was started. resection of primary sigmoid colon cancer at age 64 With the latter regimen, his glucose metabolism years. remained stable with daily oral absorption of He developed postprandial hyperglycemia from ste- dapagliﬂozin. roid administration during chemotherapy and was One month later, his carcinoembryonic antigen level referred to our outpatient clinic. had decreased dramatically from 1104 to 112.4 ng/mL, Because he was already receiving insulin therapy, we and computed tomography showed that his metastatic adjusted his insulin dosage and added a sodium glucose tumor lesions had shrunk substantially, suggesting the cotransporter (SGLT2) inhibitor (dapagliﬂozin; 5 mg/day).
Clinical Colorectal Cancer – Elsevier
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera